Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.
Early research suggests that exercise increases the number of immune cells in the blood and increases the ability of rituximab to kill CLL cells
Rituximab can be given in combination with many other medications to treat CLL or SLL.
With the introduction of BTK inhibitors to treat CLL, there has been no disparity in survival outcomes for patients of different races and ethnicities.
In this final long-term analysis of the groundbreaking MURANO trial, progression-free survival (PFS) and overall survival (OS) benefits for venetoclax-rituximab (VenR) over bendamustine-rituximab (BR) were once again confirmed.
Study shows that patients with relapsed/refractory CLL recovered immune function after fixed-duration treatment with venetoclax + rituximab.
At the 2021 annual meeting of the American Society of Hematology, CLL Society’s Medical Advisory Board Co-Chair Dr. Alex Danilov interviewed Dr. Arnon P. Kater, the lead author of this article and Chair of the Dutch CLL society, to discuss the evolving results of the Murano trial four years later. Please enjoy this interview and article about very hopeful treatment.
Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).
At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial.
This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.
One click to our most popular content.
